Sir, The BSAC recently published a change to the recommended inhibition zone diameter breakpoint for testing susceptibility of Enterobacteriaceae to amoxicillin/clavulanate (co-amoxiclav), 1 whereby the maximum zone diameter for inferring resistance was increased from 14 to 20 mm. There was no change to the MIC breakpoint, which remains at 8 mg/L. This change resulted in a significant increase in the proportion of clinical isolates reported as resistant in our laboratory, which necessitated the release of additional antibiotic susceptibilities to clinicians.
The purpose of this study was to investigate the co-amoxiclav MICs for a group of clinical isolates of Enterobacteriaceae that were inferred to be resistant according to the current BSAC criteria and compare these with two commercially available testing systems for determining MICs.
Isolates of Escherichia coli from urine samples submitted to South Devon Healthcare NHS Foundation Trust for culture between 7 and 21 June 2011 were tested for susceptibility to co-amoxiclav by disc diffusion in accordance with BSAC methodology. The growth medium was Iso-Sensitest PO7794 agar (Oxoid, Basingstoke, UK) and amoxicillin/clavulanate 30 mg discs (20 mg of amoxicillin/10 mg of clavulanate; Oxoid, Basingstoke, UK) were used. Zones of inhibition were measured after an incubation period of 18 -20 h at 358C. E. coli isolates with a zone diameter of 14 -20 mm were selected for determination of MIC, performed by Vitek 2 (bio-Mé rieux) according to the manufacturer's instructions. Etest (bioMé rieux) was also performed according to the manufacturer's instructions (2 : 1 amoxicillin/clavulanate ratio), with the exception of using Iso-Sensitest agar as outlined in BSAC recommendations.
2 Identification of E. coli was confirmed by API 20E (bioMé rieux). The validity of all three testing methods was assured by inclusion of the control strain E. coli NCTC 10418.
A total of 91 isolates had an inhibition zone diameter of 14 -20 mm by the disc diffusion method during the 2 week period and would have been interpreted as resistant according to the modified BSAC guidelines. Eighty-eight of the isolates (96.7%) were susceptible (MIC ≤8 mg/L) when tested by Vitek 2 (see Figure 1a) . The three resistant strains had MICs of 
Number of isolates Number of isolates 16 mg/L; two of these had given a zone size of 14 mm and one had a zone size of 16 mm. However, all of the 91 isolates had an MIC ≤8 mg/L when determined by Etest and would therefore have been considered as susceptible by this method (see Figure 1b) . The control sample E. coli NCTC 10418 produced zone diameters and MICs for Etest and Vitek 2 that were all within the acceptable target range of 18 -31 mm and 2 mg/L, respectively. The results of this study suggest that E. coli resistance to co-amoxiclav is being over-reported by the change in zone diameter breakpoint advocated in the current BSAC guidelines.
E. coli is the predominant cause of community and nosocomial urinary tract infection (UTI). Co-amoxiclav is often recommended as second-line treatment of uncomplicated lower UTIs that are resistant to trimethoprim and nitrofurantoin; the thirdline treatment may be a fluoroquinolone. A likely consequence of misreporting false resistance to co-amoxiclav is the unnecessary prescribing of cephalosporin and/or fluoroquinolone antibiotics, both of which are associated with an increased risk of Clostridium difficile-associated diarrhoea 3,4 and may also lead to the selection of extended-spectrum b-lactamase-producing coliforms. 5, 6 This study highlights the importance of rigorous validation of changes to susceptibility testing guidelines, not least because of the potential adverse effect on efforts to ensure good antibiotic stewardship.
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Sir, Elizabethkingia meningoseptica, formerly Chryseobacterium meningosepticum, is a non-fermentative Gram-negative bacterium and rare cause of nosocomial meningitis in adults.
1,2 Selection of appropriate therapy is difficult due to inherent resistance. We report a case of E. meningoseptica meningitis and bacteraemia in which therapeutic drug monitoring (TDM) allowed optimization of pharmacokinetic and pharmacodynamic targets and microbiological cure.
A 73-year-old patient, previously treated with craniofacial irradiation for nasopharyngeal carcinoma, had a progressive decline in cognitive function and magnetic resonance imaging showed radiation-induced encephalomalacia with a new large right frontal cyst with mass effect in the right frontal lobe. The patient was admitted for open fenestration of the intracranial cyst. Dexamethasone was initiated post-craniotomy as standard of care for reduction of swelling.
On post-operative day (POD) 3 the patient developed lethargy, fever and neck stiffness. The patient underwent a lumbar puncture, which showed cerebral spinal fluid (CSF) pleocytosis (1572 cells/mm 3 ) with neutrophilic predominance (87%), increased protein (253 mg/dL) and slight hypoglycorrhachia (54 mg/dL). Gram staining of CSF and blood revealed Gramnegative bacteria. The patient developed septic shock and empirical meropenem was initiated. The use of norepinephrine was required intermittently for 48 h for blood pressure support but the patient never suffered any renal or hepatic impairment.
On POD 6 the organism was identified as E. meningoseptica. Because of clinical deterioration, antibiotics were empirically switched to piperacillin/tazobactam, rifampicin and vancomycin. Blood cultures from POD 6 also grew E. meningoseptica. The
